Rare location of carcinoid tumour in the kidney is reported. The diagnosis was established on the basis of histological and ultrastructural investigation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors.
Oncologist
January 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
Objectives: Well-differentiated neuroendocrine tumors (NET) are highly vascular tumors characterized by their expression of vascular endothelial growth factor (VEGF). This trial investigated the activity of ramucirumab, a monoclonal antibody that targets VEGF receptor-2 (VEGFR-2) and inhibits activity of VEGF, in combination with somatostatin analog therapy in patients (pts) with advanced extra-pancreatic NET.
Methods: We conducted a single-arm phase II trial enrolling pts with advanced, progressive extra-pancreatic NET.
Neuroendocrine Tumors in Horseshoe Kidneys: A Review of the Literature With Report of a Novel Finding Expanding Their Morphologic Spectrum.
Adv Anat Pathol
November 2024
Department of Radiology, School of Medical Sciences, State University of Campinas (Unicamp), Campinas, Brazil.
Horseshoe kidney is a rare congenital anomaly with an unusually higher frequency of neuroendocrine tumors. Symptoms are rare, and, in most of the cases, are incidentally diagnosed. The clinical behavior of these tumors is heterogeneous and can be difficult to predict based on histology alone.
View Article and Find Full Text PDFAtypical carcinoid of the primary kidney with retroperitoneal metastasis 15 years later: A case report and literature review.
Urol Case Rep
January 2025
Department of Orthopedics, The First Affiliated Hospital of Wannan Medical College, Wuhu, 241001, Anhui, PR China.
Primary renal neuroendocrine tumors (NETs) are extremely rare among renal malignancies. According to pathological manifestations, carcinoid can be divided into four types: typical carcinoid, atypical carcinoid, large cell and small cell neuroendocrine carcinoma. Primary or secondary retroperitoneal carcinoid is even rarer than renal carcinoid.
View Article and Find Full Text PDFArticle Synopsis
- * The study highlights three patients with metastatic pituitary lesions linked to primary cancers of the breast, lung, and kidney, all of whom had surgical treatment at an endocrinology research center.
- * Symptoms included panhypopituitarism and chiasmal syndrome, with varying outcomes; two patients experienced disease progression while one maintained a stable condition after surgery.
Octreotide Causing Hyperkalemia: A Case Report and Review of the Literature.
Cureus
August 2024
Nephrology, State University of New York (SUNY) Downstate Health Sciences University, New York City, USA.
Article Synopsis
- Octreotide is a synthetic version of somatostatin that helps inhibit hormones like growth hormone and insulin, and is used in conditions such as acromegaly and carcinoid tumors.
- A 44-year-old man with type 2 diabetes and advanced kidney disease experienced severe hypoglycemia from sulfonylureas and was treated with octreotide, which unfortunately caused hyperkalemia as a side effect.
- This case underscores the risks of using octreotide in patients with renal impairment, highlighting the need for careful monitoring of potassium levels to prevent serious complications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!